EP4357338 - N-SUBSTITUTED PHENYLSULFONAMIDE COMPOUND AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 22.03.2024 Database last updated on 02.09.2024 | |
Former | The international publication has been made Status updated on 23.12.2022 | Most recent event Tooltip | 22.08.2024 | Change: Validation states | published on 25.09.2024 [2024/39] | 22.08.2024 | Change - extension states | published on 25.09.2024 [2024/39] | Applicant(s) | For all designated states Shanghai Leado Pharmatech Co. Ltd. Room 301, Building 12 No.999 Jiangyue Road Minhang District Shanghai 201114 / CN | [2024/17] | Inventor(s) | 01 /
WANG, Youxin Shanghai 201114 / CN | 02 /
ZHANG, Lingling Shanghai 201114 / CN | 03 /
DING, Qiang Shanghai 201114 / CN | [2024/17] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2024/17] | Application number, filing date | 22824137.8 | 10.06.2022 | [2024/17] | WO2022CN98183 | Priority number, date | CN202110666168 | 16.06.2021 Original published format: CN202110666168 | [2024/17] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022262657 | Date: | 22.12.2022 | Language: | ZH | [2022/51] | Type: | A1 Application with search report | No.: | EP4357338 | Date: | 24.04.2024 | Language: | EN | [2024/17] | Search report(s) | International search report - published on: | CN | 22.12.2022 | Classification | IPC: | C07D307/52, C07D307/79, C07D417/12, C07D405/12, C07D409/12, C07D333/20, C07D333/34, C07D207/335, C07D277/28, C07D231/12, C07D261/08, C07D233/64, C07D307/54, C07D409/14, C07D249/06, A61P29/00, A61P1/00, A61P1/04, A61P25/00, A61K31/341, A61K31/428 | [2024/17] | CPC: |
A61P1/00 (EP,CN,US);
C07D307/52 (EP,CN,US);
C07D409/12 (EP,CN,US);
A61K31/341 (US);
A61K31/343 (US);
A61K31/381 (US);
A61K31/40 (US);
A61K31/4155 (US);
A61K31/4178 (US);
A61K31/4192 (US);
A61K31/42 (US);
A61K31/426 (US);
A61K31/443 (US);
A61P1/04 (EP,CN);
A61P25/00 (EP,CN);
A61P25/04 (EP,CN);
A61P29/00 (EP,CN,US);
C07D207/323 (EP);
C07D207/325 (EP);
C07D207/335 (CN,US);
C07D231/12 (EP,CN,US);
C07D233/64 (EP,CN,US);
C07D249/06 (EP,CN,US);
C07D261/08 (EP,CN,US);
C07D277/28 (EP,CN,US);
C07D307/54 (EP,CN,US);
C07D307/79 (CN,US);
C07D333/20 (EP,CN,US);
C07D333/34 (CN,US);
C07D405/10 (EP);
C07D405/12 (EP,CN,US);
C07D407/12 (EP);
C07D409/14 (EP,CN);
C07D417/12 (EP,CN,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/17] | Title | German: | N-SUBSTITUIERTE PHENYLSULFONAMIDVERBINDUNG UND VERWENDUNG DAVON | [2024/17] | English: | N-SUBSTITUTED PHENYLSULFONAMIDE COMPOUND AND USE THEREOF | [2024/17] | French: | COMPOSÉ DE PHÉNYLSULFONAMIDE N-SUBSTITUÉ ET SON UTILISATION | [2024/17] | Entry into regional phase | 10.01.2024 | Translation filed | 10.01.2024 | National basic fee paid | 10.01.2024 | Search fee paid | 10.01.2024 | Designation fee(s) paid | 10.01.2024 | Examination fee paid | Examination procedure | 10.01.2024 | Amendment by applicant (claims and/or description) | 10.01.2024 | Examination requested [2024/17] | Fees paid | Renewal fee | 10.01.2024 | Renewal fee patent year 03 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2008038955 (CHONG KUN DANG PHARM CORP [KR], et al); | [X]CN101511800 (CHEMOCENTRYX INC [US]); | [X]WO2010126002 (SHIONOGI & CO [JP], et al); | [X]WO2014163162 (TAKEDA PHARMACEUTICAL [JP]); | [X]KR20150144121 (SFC CO LTD [KR]); | [X]WO2020097408 (NIMBUS ARTEMIS INC [US]); | [A]US2021130380 (COLE BRIDGET MCCARTHY [US], et al); | by applicant | WO2010075353 |